Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw unusually-high trading volume on Friday . Approximately 1,157,949 shares traded hands during trading, an increase of 44% from the previous session’s volume of 803,468 shares.The stock last traded at $57.26 and had previously closed at $53.36.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on DNTH. Wedbush reiterated an “outperform” rating and issued a $46.00 price target on shares of Dianthus Therapeutics in a report on Monday, December 22nd. Truist Financial lifted their price target on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Finally, HC Wainwright increased their target price on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $64.43.

Dianthus Therapeutics Trading Up 2.0%

The stock’s 50 day moving average is $43.55 and its two-hundred day moving average is $34.79. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -15.64 and a beta of 1.55.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. On average, sell-side analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Insider Activity

In other Dianthus Therapeutics news, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the completion of the transaction, the executive vice president directly owned 4,000 shares in the company, valued at approximately $152,560. The trade was a 96.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 216,538 shares of company stock valued at $8,283,175 over the last three months. 8.15% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently bought and sold shares of DNTH. Parkside Financial Bank & Trust boosted its stake in shares of Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after buying an additional 618 shares during the last quarter. Bessemer Group Inc. grew its stake in Dianthus Therapeutics by 7.8% in the 3rd quarter. Bessemer Group Inc. now owns 16,134 shares of the company’s stock valued at $635,000 after buying an additional 1,170 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics during the second quarter worth approximately $27,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Dianthus Therapeutics during the third quarter worth approximately $64,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.